Other Cancer Clinical Trials (Sarcoma)

California Pacific CURRENTS: The online journal of CPMC Research Institute

CPMC offers the following clinical trials for the treatment of sarcoma:

A Phase I/ Randomized Phase II Study of MLN0128 vs. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma

Description: This partially randomized phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic).

Investigators

  • NCI - National Cancer Institute)

Eligibility Requirements

Subjects, 18 y/o and older, with histopathologically confirmed sarcoma of one of the subtypes and who have measurable locally advanced or metastatic disease

Status

Please contact site for study status

Contacts

Peter Gasper, 415-600-3472

 

Molecular Analysis for Therapy Choice (MATCH)

Description: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists.

Investigators

  • NCI - National Cancer Institute

Clinical Trial Eligibility Requirements: Subjects, 18 y/o and older, with a have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and that has progressed following at least one line of standard systemic therapy and/or for whose disease no standard treatment exists that has been shown to prolong survival

Status

Contact site for study status

Contacts

Peter Gasper, 415-600-3472